- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00003515
Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Primitive Neuroectodermal Tumor Outside the Central Nervous System
Current therapies for Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors.
PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OVERVIEW: This is a single arm, open-label study in which patients with Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment continues up to12 months in the absence of disease progression or unacceptable toxicity.
OBJECTIVES:
- To determine the efficacy of Antineoplaston therapy in patients with Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors, as measured by an objective response to therapy (complete response, partial response or stable disease).
- To determine the safety and tolerance of Antineoplaston therapy in patients with Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors.
- To determine objective response, tumor size is measured utilizing MRI scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77055-6330
- Burzynski Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed incurable primitive neuroectodermal tumors outside the central nervous system that are unlikely to respond to existing therapy, meeting 1 of the following criteria:
- Metastatic disease
- Progressive, recurrent, or refractory disease after initial therapy, including surgery, chemotherapy, and/or radiotherapy
- Measurable disease by MRI or CT scan
- Tumor must be at least 2 cm
PATIENT CHARACTERISTICS:
Age:
- 6 months and over
Performance status:
- Karnofsky 60-100%
Life expectancy:
- At least 2 months
Hematopoietic:
- WBC at least 2,000/mm^3
- Platelet count at least 50,000/mm^3
Hepatic:
- No hepatic insufficiency
- Bilirubin no greater than 2.5 mg/dL
- SGOT and SGPT no greater than 5 times upper limit of normal
Renal:
- No renal insufficiency
- Creatinine no greater than 2.5 mg/dL
- No history of renal conditions that contraindicate high dosages of sodium
Cardiovascular:
- No uncontrolled hypertension
- No history of congestive heart failure
- No history of other cardiovascular conditions that contraindicate high dosages of sodium
Pulmonary:
- No serious lung disease, such as chronic obstructive pulmonary disease
Other:
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for 4 weeks after study participation
- No active infection
- No nonmalignant systemic disease
- Not a high medical or psychiatric risk
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 4 weeks since prior immunotherapy
- No concurrent immunomodulating agents
Chemotherapy:
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
Endocrine therapy:
- Concurrent corticosteroids allowed
Radiotherapy:
- See Disease Characteristics
- At least 8 weeks since prior radiotherapy
Surgery:
- See Disease Characteristics
- Recovered from prior surgery
Other:
- Prior cytodifferentiating agents allowed
- No prior antineoplastons
- No other concurrent antineoplastic agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Antineoplaston therapy
Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months.
Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
|
Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Other Names:
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000066558
- BC-PN-02 (Other Identifier: Burzynski Research Institute)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primitive Neuroectodermal Tumor
-
Mayo ClinicCompletedEwing Sarcoma of Bone | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingMedulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Anaplastic Medulloblastoma | Supratentorial Embryonal Tumor, Not Otherwise SpecifiedUnited States, Canada, Australia, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnEwing Sarcoma of Bone | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Childhood Medulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedMetastatic, Cerebral Primitive Neuroectodermal TumorsFrance
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorUnited States
-
Burzynski Research InstituteCompletedChildhood CNS Primitive Neuroectodermal TumorUnited States
-
St. Jude Children's Research HospitalUniversity of Florida; University of Tennessee; Nemours Children's ClinicActive, not recruitingDesmoplastic Small Round Cell Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Ewing Sarcoma of Bone or Soft Tissue | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorUnited States
-
Dana-Farber Cancer InstituteHarvard University; Conquer Cancer Foundation; Alex's Lemonade Stand Foundation; Sam Day FoundationRecruitingEwing Sarcoma of Bone | Ewing Sarcoma | Peripheral Primitive Neuroectodermal Tumor | Peripheral Primitive Neuroectodermal Tumor of Bone | High-grade Osteosarcoma | Ewing Sarcoma of Soft Tissue | Peripheral Primitive Neuroectodermal Tumor of Soft TissueUnited States
Clinical Trials on Antineoplaston therapy (Atengenal + Astugenal)
-
Burzynski Research InstituteCompletedLow Grade AstrocytomasUnited States
-
Burzynski Research InstituteTerminatedMalignant MesotheliomaUnited States
-
Burzynski Research InstituteTerminatedStage IV Non-small Cell Lung CancerUnited States
-
Burzynski Research InstituteTerminatedStage IV Ovarian Cancer | Stage III Ovarian CancerUnited States
-
Burzynski Research InstituteTerminatedSmall Intestine CancerUnited States
-
Burzynski Research InstituteTerminatedNeuroblastomaUnited States
-
Burzynski Research InstituteCompletedMalignant Brain TumorsUnited States
-
Burzynski Research InstituteTerminated
-
Burzynski Research InstituteTerminatedUnknown Primary CarcinomaUnited States
-
Burzynski Research InstituteTerminatedMetastatic Prostate CancerUnited States